Myeloma

A navigator-designed, proactive, weekly, telephone support call to help patients with blood cancers manage their symptoms between appointments was able to significantly reduce unplanned hospitalizations at a Colorado cancer center.

Jasmine Martin, Director, West Region Medical Science Liaison Team, Takeda Oncology, discusses oral adherence.

Sandra Spoelstra, PhD, RN, Assistant Professor, College of Nursing, Michigan State University, discusses educating patients about oral agents.

Amanda Yopp, NP, Clinical Nurse Educator, Takeda Oncology, discusses educating patients before they enroll on a clinic trial.

Investigational monoclonal antibodies, such as daratumumab and elotuzumab, could potentially change the role of stem cell transplantation for patients with multiple myeloma.

Kyprolis doubled progression-free survival versus Velcade in patients with relapsed multiple myeloma in the phase 3 ENDEAVOR trial.

The FDA has approved Farydak (panobinostat) in combination with Velcade (bortezomib) and dexamethasone for patients with multiple myeloma who receive prior treatment with Velcade and an immunomodulatory (IMiD) agent, based on results of the PANORAMA-1 trial.

Lauren Hill, a student-athlete at Mount St. Joseph University, has inspired many with her commitment to fulfilling her dream of playing college basketball despite a diagnosis of diffuse intrinsic pontine glioma (DIPG), an aggressive type of brain tumor.

The FDA has approved Revlimid plus dexamethasone in newly diagnosed patients with multiple myeloma based on findings from the phase 3 FIRST trial.

Ixazomib, also known as MLN9708, met its primary endpoint of improving progression-free survival at an interim analysis of a phase 3 trial of relapsed or refractory multiple myeloma.

Anne Quinn Young, of the Multiple Myeloma Research Foundation, discusses some of the antibodies that are being studied in multiple myeloma.

Brian G.M. Durie, an expert in multiple myeloma at Cedars-Sinai in Los Angeles, Calif., and chairman of the International Myeloma Foundation, discusses the ASPIRE trial for patients with relapsed myeloma.

The Food and Drug Administration's calendar for making decisions on new cancer drugs and indications is taking shape for 2015, and the clock is ticking on at least 13 applications for novel agents and new therapeutic settings for existing drugs.

Anne Young Quinn, of the MMRF, explains the catalyst behind the CoMMpass study and how it may be changing the future of myeloma treatment.

Treatment with the experimental agent elotuzumab in combination with Revlimid and dexamethasone demonstrated encouraging efficacy in patients with relapsed/refractory multiple myeloma in a phase 1b/2 study.

Anti-CD38 monoclonal antibodies continue to demonstrate promise across a variety of settings, generating excitement that a new treatment paradigm could be on the horizon for patients with multiple myeloma.

Adding the proteasome inhibitor Kyprolis (carfilzomib) after Revlimid (lenalidomide) in patients with relapsed multiple myeloma showed significant delay of disease progression.

Patients with multiple myeloma fare better with continuous Revlimid (lenalidomide).

Updates from the annual meeting of the American Society of Hematology.

Robert Kyle is changing lives through research.

New treatments for multiple myeloma target the disease in different ways.

The latest in cancer prevention, diagnosis & treatment.

Velcade-based therapy shows benefit in multiple myeloma trial called GIMEMA.

When considering a stem cell transplantation, patients with cancer must be willing to take a chance.

Cancer research updates from the San Antonio Breast Cancer Symposium and American Society of Hematology.

Research into vaccine therapy for cancer is extending to many cancer types.

An introduction to multiple myeloma.

Learn how multiple myeloma is diagnosed.

Learn how multiple myeloma is staged.

Learn about treatment options for multiple myeloma.